Semax Mechanisms and Study Designs: What Published Research Reports

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This overview summarizes mechanisms and study designs reported in the provided peer‑reviewed and primary literature records that examine Semax (ACTH(4-7)PGP and related ACTH-like peptides). The article focuses on peptide identity, proposed molecular mechanisms, experimental models and designs, outcomes measured, and protocol details reported in the reviewed excerpts. Evidence is predominantly preclinical with limited human imaging data and variable methodological detail in the excerpts.

Research scope and peptide identity

Semax is described in the reviewed sources as an ACTH-like synthetic heptapeptide (sequence reported as Met-Glu-His-Phe-Pro-Gly-Pro or ACTH(4-7)PGP) derived from the N-terminal domain of adrenocorticotropic hormone and coupled to a Pro-Gly-Pro tripeptide; sources identify Semax by this ACTH(4-7)PGP descriptor and as an analog of ACTH(4-10). ^{[S6] [S3] [S5]}

The reviewed literature addresses Semax in several research contexts including neuroprotection after ischemia and spinal cord injury, modulation of neurotrophin signaling, transcriptomic effects after experimental stroke, interactions with metal ions in vitro, and acute functional brain connectivity effects in healthy human participants. ^{[S5] [S3] [S9] [S6] [S2]}

Mechanisms discussed in cited studies

Several sources propose neurotrophin-related mechanisms: Semax increased transcription of Bdnf and Trk receptor genes after experimental cerebral ischemia in rats and regulated hippocampal BDNF and TrkB expression in rat studies, supporting a neurotrophin-mediated pathway in ischemic and cognitive contexts. ^{[S9] [S10]}

Transcriptomic studies report that Semax and related ACTH-like peptides modulate hundreds to thousands of differentially expressed genes (DEGs) after transient middle cerebral artery occlusion (tMCAO) in rats, with influences on immune- and neurosignaling-related pathways, neurogenesis, angiogenesis, protein kinase and growth factor-related genes, and partial normalization of ischemia-induced expression disturbances. ^{[S5] [S7]}

A 2025 mechanistic study in a spinal cord injury (SCI) mouse model linked Semax to modulation of lysosomal membrane permeabilization (LMP), oxidative stress, ubiquitination pathways and pyroptosis, and identified regulation of the ubiquitin-specific protease USP18 and a proposed interaction with the μ-opioid receptor (Oprm1) leading to deubiquitination of FTO as part of the peptide's reported effects. ^[S3]

Chemical/biophysical data indicate that N-terminal acetylation of Semax alters its metal (Cu(II), Zn(II)) coordination chemistry and redox properties and that the free N‑terminal amino group is important for protection against Cu(II)-induced toxicity in a SH-SY5Y neuroblastoma cell line, suggesting that peptide modifications can change biochemical interactions relevant to biological activity. ^[S6]

A broader review context situates Semax among neuroactive peptides that have been reported to enhance brain-derived neurotrophic factor (BDNF) and other neuroplasticity pathways (for example, HGF/c‑Met), linking Semax to neuroplasticity-relevant signaling in review summaries of therapeutic peptides. ^[S1]

Study models and experimental designs

Human resting-state functional MRI was used to assess acute functional connectivity (FC) changes after administration of Semax (compared with Selank and placebo) in a cohort of 52 healthy participants, with scans performed before and at short intervals after injection. ^[S2]

Rodent ischemia/stroke models feature prominently: transient middle cerebral artery occlusion (tMCAO) and permanent middle cerebral artery occlusion models in rats were used to study Semax and related ACTH-like peptides with transcriptomic (RNA‑Seq) and histological endpoints at early post‑ischemia time points (e.g., 4.5 h and 24 h), and region-specific analyses of frontal cortex and striatum were reported. ^{[S5] [S7] [S9]}

A mouse model of spinal cord injury (female C57BL/6 mice with an impact at T9–T10) was employed to study Semax effects on functional recovery, cellular markers of injury, oxidative stress, LMP-related pyroptosis and ubiquitination using behavioral scoring and molecular assays. ^[S3]

In vitro cellular models included PC12 cells used in neuroinflammation contexts and SH-SY5Y human neuroblastoma cells used for metal ion toxicity and peptide modification studies; these models were analyzed using biochemical and imaging techniques. ^{[S3] [S6]}

Outcomes measured in the reviewed sources

Neurotrophin gene expression changes (Bdnf, Trk receptors, Ngf, Nt-3) were measured in cortical and hippocampal tissue after ischemic injury or peptide treatment in rat models. ^{[S9] [S10]}

Transcriptomic outcomes (RNA-Seq) quantified differentially expressed genes (DEGs) following ischemia and peptide administration in rat frontal cortex and striatum, with reported DEG counts and pathway annotations indicating effects on immune, neurotransmitter, neurogenesis, angiogenesis and kinase/growth factor-related processes. ^{[S5] [S7]}

Functional and behavioral outcomes after spinal cord injury included footprint analysis, Basso locomotor scores and inclined plane testing to evaluate locomotor/functional recovery alongside histochemical and ultrastructural markers. ^[S3]

Cellular and molecular endpoints reported include markers of lysosomal membrane permeabilization (LMP), oxidative stress, pyroptosis, ubiquitination and regulation of specific deubiquitinases (USP18) and targets such as FTO, assessed by immunofluorescence, Western blot, RT‑qPCR and transmission electron microscopy in SCI and cell models. ^[S3]

Acute changes in whole-brain resting-state functional connectivity (FC) between regions such as the amygdala and temporal cortex were detected by resting‑state fMRI after Semax or Selank administration in healthy human participants. ^[S2]

In vitro metal‑binding and toxicity outcomes included characterization of Cu(II) and Zn(II) coordination species with Semax and N‑terminally acetylated Semax (Ac‑Semax), redox stability assessments, and cell viability/toxicity assays in SH‑SY5Y cells. ^[S6]

Reported study-design and protocol details

Human resting-state fMRI study: scans were acquired before and at 5 and 20 minutes after injection of Semax, Selank, or placebo in 52 healthy participants; regions of interest included bilateral amygdala and dorsolateral prefrontal cortex, and between-group differences in FC (e.g., right amygdala to right temporal cortex) were analyzed. ^[S2]

Spinal cord injury (SCI) mouse study: the model used female C57BL/6 mice with an impact at T9–T10; functional recovery was evaluated using histochemical methods, footprint analysis, Basso scores and inclined plane tests; molecular analyses included immunofluorescence, Western blot, RT‑qPCR, transmission electron microscopy, RNA sequencing, network pharmacology and molecular docking to identify targets such as μ‑opioid receptor and USP18. ^[S3]

Rat stroke (tMCAO) transcriptomic studies: RNA‑Seq analyses were reported at 4.5 h and 24 h after tMCAO in ipsilateral frontal cortex (and at 24 h in penumbra-associated frontal cortex and striatum), with counts of DEGs reported for Semax and ACTH(6-9)PGP treatment conditions and pathway annotations describing immune and neurosignaling effects; previous histological neuroprotection at 24 h was referenced. ^{[S5] [S7]}

In vitro metal coordination and cell assays: Semax and N‑terminally acetylated Semax (Ac‑Semax) were characterized for Cu(II) and Zn(II) complex formation and redox properties at physiological pH; effects on Cu(II)-induced toxicity were assessed in SH‑SY5Y neuroblastoma cells and Zn(II) influx/localization was visualized by confocal microscopy. ^[S6]

Primary literature ischemia timing: in a permanent middle cerebral artery occlusion rat model Semax increased cortical transcription of neurotrophin genes at 3 h (Bdnf, TrkA/TrkC) and at 24 h (Ngf, Nt-3) after ischemia, as reported in the provided primary literature excerpt. ^[S9]

Rat hippocampus study: Semax administration upregulated hippocampal BDNF and TrkB expression in rats, as reported in the provided primary literature excerpt. ^[S10]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Limitations and research gaps

• Most reviewed evidence is preclinical (rodent models and in vitro) with only one human fMRI study excerpt; clinical efficacy, safety, dosing and route details are not provided in these excerpts.
• Many protocol specifics (peptide amounts/doses, precise administration routes, dosing frequency and treatment durations) are not reported in the provided source excerpts.
• Mechanistic links (for example between μ-opioid receptor engagement and downstream deubiquitination events) are reported in single studies and may require independent replication and fuller methodological detail to establish causality.

Documentation checklist

• Confirm peptide identity and sequence from primary source material before experimental planning.
• Verify animal model details (species, sex, injury location, timepoints) from full-text methods before replication.
• Obtain complete dosing, administration route and safety data from full manuscripts or regulatory documents (not provided in these excerpts) prior to in vivo work.
• For transcriptomic endpoints, ensure RNA-Seq experimental design and sequencing depth are appropriate and consult full methods for normalization and DEG criteria.
• For imaging studies, confirm scanner parameters, injection formulation and timing from the primary report.

Related research supplies

• RNA extraction and RNA‑Seq library preparation kits
• Access to a resting‑state fMRI scanner and compatible head coils
• Confocal fluorescence microscope for cellular Zn(II) imaging
• Transmission electron microscope for ultrastructural analysis
• Standard molecular biology reagents for Western blot, RT‑qPCR and immunofluorescence
• Behavioral testing apparatus for rodents (inclined plane, footprint analysis setups, scoring benches)

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon → (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon → (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

More Semax research

• Semax Human Studies vs Preclinical Research
• Semax Reported Routes, Amounts, and Study Designs
• Semax BDNF and Gene-Expression Research
• Semax Benefits, Uses, and Protocols: What Published Research Reports
• How to Read a Peptide COA Without Getting Fooled
• Peptide Purity vs Identity Testing Explained

Sources and references

1. [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
2. [S2] Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV. Functional Connectomic Approach to Studying Selank and Semax Effects.. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020. PMID: 32342318. DOI: 10.1134/S001249662001007X
3. [S3] Liu R, Chen Y, Huang H, Li X, Lv J, Jiang L. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.. British journal of pharmacology. 2025. PMID: 40692165. DOI: 10.1111/bph.70122
4. [S4] Tarasov VV, Kudryashov NV, Chubarev VN, Kalinina TS, Barreto GE, Ashraf GM. Pharmacological Aspects of Neuro-Immune Interactions.. Current pharmaceutical design. 2018. PMID: 28875850. DOI: 10.2174/1381612823666170829135115
5. [S5] Filippenkov IB, Shpetko YY, Stavchansky VV, Denisova AE, Gubsky LV, Andreeva LA. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.. Biomedicines. 2024. PMID: 39767736. DOI: 10.3390/biomedicines12122830
6. [S6] Magrì A, Tabbì G, Giuffrida A, Pappalardo G, Satriano C, Naletova I. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties.. Journal of inorganic biochemistry. 2016. PMID: 27586814. DOI: 10.1016/j.jinorgbio.2016.08.013
7. [S7] Filippenkov IB, Shpetko YY, Ales DA, Stavchansky VV, Denisova AE, Yuzhakov VV. Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.. International journal of molecular sciences. 2025. PMID: 40650034. DOI: 10.3390/ijms26136256
8. [S8] Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.. Frontiers in aging. 2026. PMID: 42021992. DOI: 10.3389/fragi.2026.1790247
9. [S9] Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia. primary literature. PMID:
10. [S10] Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. primary literature. PMID:

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.